Nature Medicine retracted a high-profile randomized Phase 3 study claiming that giving PD-1 immunochemotherapy earlier in the day improved outcomes for advanced non-small cell lung cancer. The journal said editors no longer had confidence in the integrity of the results after identifying multiple problems during a four-month investigation. The paper, titled “Time-of-day immunotherapy in non-small cell lung cancer: a randomized phase 3 trial,” reported that patients receiving the first four cycles of PD-1 inhibitor combined with chemotherapy before 3 p.m. experienced a 60% lower risk of disease progression or death, with median progression-free survival of 11.3 months versus 5.7 months. The retraction specifically affects the evidentiary foundation for timing-based administration strategies and reopens questions about protocol adherence and the reliability of efficacy and safety patterns. It also intensifies scrutiny of unconventional trial parameters that can be difficult to standardize across sites. For drug developers, the move is a reminder to ensure rigorous operational controls when testing novel clinical hypotheses beyond drug selection and dosing.